Skip to main content

Daniel T. Kajunski

Member

[email protected]

+1.617.348.1715

Share:

Dan is a corporate and securities attorney whose practice spans the full gamut of corporate law. He has advised clients for nearly two decades in public and private equity and debt financings, securities law matters, mergers and acquisitions, and strategic advice on a broad range of other corporate matters. He capably counsels public and private companies with offerings, compliance, and securities questions and leads buyers and sellers throughout the transaction process. Dan represents life sciences companies as well as clients in other technology fields, financial services, and professional services firms.

Dan’s practice focuses primarily on venture finance, securities law and offerings, mergers and acquisitions, and general business and corporate law, primarily for life sciences and technology companies.

VCs, strategic investors, and issuers rely on Dan’s extensive experience in private fund raising, including equity and debt financings. Public companies also turn to him in connection with public and private offerings and their securities law and compliance needs. In addition, both buyers and sellers engage Dan to counsel them in complicated mergers and acquisitions. Dan also regularly advises both private and public companies at various stages of development on general corporate matters.

Prior to joining the firm, Dan served as a law clerk to the justices of the Superior Court of Massachusetts. While in law school, he served as a staff author and comment editor for the Suffolk University Law Review.

Education

  • Suffolk University Law School (JD)
  • Saint Anselm College (BA)

Experience

Offerings for Public Companies

  • Represented Vertex Pharmaceuticals (Nasdaq: VRTX) in over $2.0 billion in equity and debt offerings since 2006
  • Represented ImmunoGen (Nasdaq: IMGN) in approximately $350 million in equity offerings since 2008
  • Represented Amedica (Nasdaq: AMDA) in its IPO
  • Represented the underwriters in the IPO of Calithera Biosciences (Nasdaq: CALA)
  • Represented the underwriters in the IPO of American Depositary Shares of GW Pharmaceuticals (Nasdaq: GWPH) and two additional follow-on offerings

Venture Capital & Strategic Financings

  • Represented a public technology company in the semiconductor and life sciences industry (Nasdaq) in multiple strategic investments
  • Represented a public medical device company (NYSE) in multiple strategic investments
  • Represented Clarus Ventures in its investments in Ophthotech (Nasdaq: OPHT), VBI Vaccines (Nasdaq: VBIV), TyRx Pharma, and Link Medicine
  • Represented a public biotechnology company (Nasdaq) in its strategic equity investment in a private biotechnology company
  • Represented Style Me Pretty in its strategic investment from AOL (NYSE: AOL)
  • Represented Synchroneuron in multiple equity financings
  • Represented TransMolecular in multiple equity and debt financings
  • Represented Ion Torrent Systems in multiple equity financings
  • Represented I-Pulse in multiple equity financings
  • Represented TransForm Pharmaceuticals in multiple equity financings
  • Represented Hemera Biosciences in its Series A financing


Mergers & Acquisitions

  • Represented Brooks Automation (Nasdaq: BRKS) in its purchase of BioStorage Technologies
  • Represented a public biotechnology company (Nasdaq) in its entering into a merger option to acquire a private biotechnology company
  • Represented Clarus Ventures in the reverse merger of VBI Vaccines (Nasdaq: VBIV) with Paulson Capital
  • Represented Orchid BioSciences (Nasdaq: ORCH) in its sale to Laboratory Corporation of America (NYSE: LH)
  • Represented QIAGEN (Nasdaq: QGEN) in its purchase of SA Biosciences
  • Represented TransMolecular in its sale to Morphotek (a subsidiary of Eisai Co. (Tokyo Stock Exchange))
  • Represented Auspice in its sale to the ARRIS Group (Nasdaq: ARRS)
  • Represented EPIX Pharmaceuticals (Nasdaq: EPIX) in its merger with Predix Pharmaceuticals
  • Represented TransForm Pharmaceuticals in its sale to Johnson & Johnson (NYSE: JNJ)
  • Represented FastClick (Nasdaq: FSTC) in its sale to ValueClick (Nasdaq: VCLK)

Viewpoints

Securities & Capital Markets Viewpoints Thumbnail
Read about the SEC’s extension of conditional relief from filing deadlines and mailing obligations as a result of COVID-19 to July 1, 2020.
Read more
Securities & Capital Markets Viewpoints Thumbnail
Read about the SEC's new Guidance on Manual Signatures Required under Rule 302(b) of Regulation S-T as a Result of Coronavirus (COVID-19).
Read more
Securities & Capital Markets Viewpoints Thumbnail
Read about the SEC’s March 4 order granting issuers and other persons relief from some securities law requirements in the event of disruptions due to the coronavirus.
Read more
Securities & Capital Markets Viewpoints Thumbnail

SEC Guidance on Key Performance Indicators and Metrics in MD&A and Three New MD&A C&DIs

February 26, 2020 | Advisory | By Daniel T. Kajunski, Amanda Mei

This advisory covers guidance from the SEC on the disclosure of key MD&A performance metrics and three new CD&Is.
Read more
Securities & Capital Markets Viewpoints Thumbnail

SEC Proposes Expanding “Accredited Investor” and “Qualified Institutional Buyer” Definitions

February 3, 2020 | Article | By Daniel T. Kajunski, John J. Thomas III

This article reviews an SEC proposal to open private capital markets to new investors by expanding its definitions of “accredited investor” and “qualified institutional buyer.”
Read more
Securities & Capital Markets Viewpoints Thumbnail

SEC Reminds Audit Committees of Their Oversight Role

January 30, 2020 | Advisory | By Daniel T. Kajunski, Zane Polston

Read about the SEC’s December 30, 2019 statement on the role of public company audit committees in financial reporting and the oversight responsibilities of audit committees.
Read more
Viewpoint Thumbnail

SEC Provides Guidance and Proposes Amendments to Shareholder Proposal Rules

December 3, 2019 | Alert | By Daniel T. Kajunski, Zachary Liebnick

Read about the SEC’s proposed rule amendments related to shareholder proposals and its guidance for companies seeking to exclude a shareholder proposal under the “ordinary business exception.”
Read more

Events

Speaker
Feb
11
2015

Public Company Director 101

Corporate Directors Group

Webinar